Xie et al. [135] reported that Sox8 enhances chemoresistance and upregulates CSC markers, while Sox8 knockdown increases chemosensitivity to cisplatin both in vitro and in vivo by reducing CD24+CD44+ CSC markers and tumor volume. Here, CD44 is linked to neoplasm.